Abstract Introduction Sub-Saharan African countries are introducing integrase strand
transfer inhibitors (INSTIs) in their ART programmes as the preferred first-line regimen, and …

Objectives To investigate the prevalence and patterns of major and accessory resistance
mutations associated with integrase strand transfer inhibitors (INSTIs), across diverse HIV-1 …

Abstract Objectives In Cameroon, the integrase (IN) strand transfer inhibitor (INSTI)
dolutegravir was recently introduced for the treatment of HIV-1 infection. Since pretreatment …

Background Transition to dolutegravir-based regimens in resource-limited settings (RLS)
requires prior understanding of HIV-1 integrase variants and conserved regions. Therefore …

Data on integrase resistance patterns in low-and middle-income countries (LMICs) is scarce.
We assessed genotypic drug resistance in 43 patients with virological failure on integrase …

To ensure the long-term efficacy of dolutegravir (DTG), we evaluated the genotypic profile in
viral reservoirs among patients on third-line (3L) antiretroviral therapy (ART) in Cameroon …

Background Despite the scale-up of ART and the rollout in Tanzania of dolutegravir, an
integrase strand transfer inhibitor (INSTI), treatment success has not been fully realized. HIV …

Background Due to the high prevalence of resistance to NNRTI-based ART since 2018,
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …

Objective: Dolutegravir (DTG) is now a preferred component of first-line antiretroviral therapy
(ART). However, prevalence data on natural resistance to integrase inhibitors [integrase …

Objectives HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though
efficacy and resistance data for non-B subtypes are limited. Two recent trials have identified …